Combination anti-HIV antibodies to achieve antiretroviral therapy-free virological suppression in infected individuals.
Combination anti-HIV antibodies to achieve antiretroviral therapy-free virological suppression in infected individuals.
复制标题
DOI：
10.1002/ctm2.1057
复制
发表时间：
2022-09
影响因子：
10.6
通讯作者：
Chun, Tae-Wook
中科院分区：
文献类型：
--
作者：
Rai, M. Ali;Chun, Tae-Wook
在过去的26年里，抗逆转录病毒疗法(ART)的发现和广泛实施导致了艾滋病毒疾病管理的显著改善，并显著降低了与艾滋病毒有关的发病率和死亡率。1绝大多数坚持抗逆转录病毒疗法的艾滋病毒感染者可以抑制他们的血浆病毒血症。然而，抗逆转录病毒疗法不能治愈，艾滋病毒感染者必须继续终身治疗，以维持病毒学抑制。3、4为了减少与长期抗逆转录病毒疗法相关的并发症(依从性、副作用、耐药性和经济考虑)，已经做出了重大努力，寻找有效的替代方案，可以在受感染的个体中导致不含抗逆转录病毒药物的病毒学抑制。然而，尽管进行了十多年的紧张研究，找到艾滋病毒治愈方法的前景仍然难以捉摸，如果不是不可能的话。6相反，一种间歇给药长效治疗剂的方法已经出现，作为在感染者中实现病毒学抑制的替代方案，这可能不一定消除先前存在的感染细胞。3在这方面，长效注射抗逆转录病毒药物有望以很少的剂量抑制血浆病毒血症。7-9此外，抗HIV的广谱中和单抗(BNAbs)已成为一种有希望的治疗方式，可在较长时间内持久抑制血浆病毒血症。10、11
Over the past 26 years, the discovery and widespread implementation of antiretroviral therapy (ART) has led to dramatic improvements in the management of HIV diseases and a marked reduction of HIV-related morbidity and mortality. 1 The vast majority of HIV-infected individuals who are adherent to ART can suppress their plasma viremia. 2 However, ART is not curative and HIV-infected individuals must continue life-long therapy to maintain virologic suppression. 3, 4 To mitigate the complications associated with long-term ART (adherence, side effects, resistance, and economic considerations), significant efforts have been made to find effective alternatives that could lead to ART-free virologic suppression in infected individuals. 5 However, despite more than a decade of intense research, the prospects for finding a cure for HIV remain elusive, if not impossible. 6 Rather, an approach involving intermittent administration of long-acting therapeutic agents, which may not necessarily eliminate the pre-existing infected cells, has emerged as an alternative to achieve virologic suppression in infected individuals. 3 In this regard, long-acting injectable antiretroviral drugs hold promise for suppressing plasma viremia with infrequent dosing. 7–9 In addition, broadly neutralizing monoclonal antibodies (bNAbs) against HIV have emerged as a promising therapeutic modality to achieve durable suppression of plasma viremia for extended periods. 10, 11
登录
查看更多内容
DOI：
10.1126/science.aaf1279
发表时间：
2016-05-20
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Lu CL;Murakowski DK;Bournazos S;Schoofs T;Sarkar D;Halper-Stromberg A;Horwitz JA;Nogueira L;Golijanin J;Gazumyan A;Ravetch JV;Caskey M;Chakraborty AK;Nussenzweig MC
通讯作者：
Nussenzweig MC
小鼠，猕猴和男性：对HIV-1的抗体免疫疗法广泛中和。
影响因子：
30.3
作者：
Nishimura Y;Martin MA
通讯作者：
Martin MA
影响因子：
64.8
作者：
Scheid, Johannes F.;Horwitz, Joshua A.;Bar-On, Yotam;Kreider, Edward F.;Lu, Ching-Lan;Lorenzi, Julio C. C.;Feldmann, Anna;Braunschweig, Malte;Nogueira, Lilian;Oliveira, Thiago;Shimeliovich, Irina;Patel, Roshni;Burke, Leah;Cohen, Yehuda Z.;Hadrigan, Sonya;Settler, Allison;Witmer-Pack, Maggi;West, Anthony P., Jr.;Juelg, Boris;Keler, Tibor;Hawthorne, Thomas;Zingman, Barry;Gulick, Roy M.;Pfeifer, Nico;Learn, Gerald H.;Seaman, Michael S.;Bjorkman, Pamela J.;Klein, Florian;Schlesinger, Sarah J.;Walker, Bruce D.;Hahn, Beatrice H.;Nussenzweig, Michel C.;Caskey, Marina
通讯作者：
Caskey, Marina
DOI：
10.1038/s41577-022-00753-w
发表时间：
2023-03
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
通讯作者：
--
影响因子：
168.9
作者：
Overton, Edgar T.;Richmond, Gary;Spreen, William
通讯作者：
Spreen, William